Mid-stage trial results of Abbott Laboratories’ oral hepatitis C drug ABT-450/r have impressed at the American Liver Disease congress. The …
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?

